Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W8XT
|
|||
| Former ID |
DIB000683
|
|||
| Drug Name |
Mibefradil
|
|||
| Synonyms |
Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Withdrawn from market | [2], [3] | ||
| Company |
Tau therapeutics; cavion
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H38FN3O3
|
|||
| Canonical SMILES |
CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
|
|||
| InChI |
1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
|
|||
| InChIKey |
HBNPJJILLOYFJU-VMPREFPWSA-N
|
|||
| CAS Number |
CAS 116644-53-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9431, 7979984, 8186987, 11111472, 14933121, 14933122, 26755047, 43118024, 46504498, 47276715, 48416277, 50064211, 50110875, 51068792, 53788328, 53801058, 57314055, 85788182, 90340964, 96024905, 103229908, 104011327, 104321323, 117509413, 124749965, 128037075, 134338995, 135047604, 137006402, 142794297, 160964663, 163620961, 163686283, 176250376, 179149650, 185998774, 198963086, 215784885, 223440331, 223554765, 225039582, 226424915, 242060284, 250133489, 251971143, 252479748, 252655656
|
|||
| ChEBI ID |
CHEBI:6920
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) | Target Info | Inhibitor | [4] |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | Corticotropin-releasing hormone | |||
| NCAM signaling for neurite out-growth | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2522). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000236) | |||
| REF 4 | Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.